HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Historical aspects and milestones in the development of effective treatment for hairy cell leukemia.

Abstract
Hairy cell leukemia (HCL) is a rare B-cell lymphoproliferative disorder, but is gratifying to treat for both physicians and patients. During the 50 years since its initial description as a clinical entity, hematologists have been fascinated by the bizarre appearance of the malignant cell with its hair-like projections. Therapeutic strategies have evolved from splenectomy to interfere to the purine analogues which have become the treatments of-choice and are very effective. Immunoconjugate Therapy with BL22 (anti-CD22 [corrected] antibody linked to truncated to Pseudomonas exotoxin) represents the newest milestone in the development of effective treatment for hairy cell leukemia.
AuthorsMartin S Tallman, Aaron Polliack
JournalLeukemia & lymphoma (Leuk Lymphoma) Vol. 50 Suppl 1 Pg. 2-7 (Oct 2009) ISSN: 1029-2403 [Electronic] United States
PMID19814690 (Publication Type: Historical Article, Journal Article, Review)
Chemical References
  • Immunoconjugates
  • Purines
Topics
  • Combined Modality Therapy
  • History, 20th Century
  • History, 21st Century
  • Humans
  • Immunoconjugates (therapeutic use)
  • Leukemia, Hairy Cell (drug therapy, surgery)
  • Medical Oncology (history, methods, trends)
  • Purines (antagonists & inhibitors, therapeutic use)
  • Splenectomy
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: